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ABSTRACT 
Objective: The present research work aims to develop and validate a selective and highly sensitive method for the determination of apixaban in 
human plasma using liquid chromatography-tandem mass spectrometry (LC-MS/MS). 
Methods: 200 µl of sodium heparin plasma samples were acidified and clean-up was performed by using solid-phase extraction (SPE). Apixaban 
13C D3 was used as an internal standard (deuterated) to lower the relative matrix effects and a single step SPE was employed for sample clean up. 
10 µl of SPE eluent was loaded onto Hypersil Beta Basic C18, 100×4.6 mm, 5 µ column for highly selective chromatographic separation using an 
isocratic mobile phase. 2 mmol ammonium acetate in water and acetonitrile were delivered by using a quaternary low-pressure gradient pump 
without premixing at a minimum flow rate of 0.50 ml/min.  
Results: LC-MS/MS method was successfully developed and validated to demonstrate the lowest detection limit of 0.05 ng/ml and a linear dynamic 
range from 1-250 ng/ml with r2>0.99. Method development and validation results proved that the method is selective and highly sensitive for the 
determination of apixaban in human plasma using LC-MS/MS. 
Conclusion: Current method can be applied for both therapeutic drug monitoring (TDM) and pharmacokinetic (PK) study analysis.  
Keywords: Human Plasma, Liquid Chromatography-Tandem, Mass spectrometry 




Apixaban is a direct oral anticoagulant used in the management of 
thromboembolism and has gained importance as an alternative 
replacement to the vitamin K antagonists such as warfarin [1]. 
Therapeutic dose of apixaban results in nanogram level plasma 
concentrations. Therefore, it is evident to use a validated method for 
the estimation of apixaban in biological matrices like human plasma 
either for pharmacokinetic (PK) study analysis [2] or for therapeutic 
drug monitoring (TDM). LC-MS/MS is the only advanced technology 
that allows highly sensitive and selective-high throughput analysis 
even with low sample volumes. Moreover, it requires minimal and 
simple sample preparation procedures. Though several methods are 
available for determination of apixaban in human plasma or serum on 
LC-MS/MS [3-12], they were applied either for PK study analysis or for 
TDM but not for both. Therefore, the objective of the current study was 
to develop and validate a highly sensitive method with the lowest 
possible sample volumes, so that the same method can be further used 
for TDM also apart from PK study analysis.  
 
 
Fig. 1: Structure of apixaban 
Apixaban is chemically described as 1-(4-methoxyphenyl)-7-oxo-
6-[4-(2-oxopiperidin-1-yl) phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo 
[3,4c] pyridine-3-carboxamide. Its molecular formula is C25H25N5O4, 
which corresponds to a molecular weight of 459.50. Apixaban has 
the following structural formula [13]. 
MATERIALS AND METHODS 
Reagents and chemicals 
Methanol (gradient grade), acetonitrile (gradient grade), 
orthophosphoric acid (guaranteed reagent grade) was purchased from 
Merck. Ammonium acetate (reagent grade) was purchased from Sigma 
Aldrich. Water (liquid chromatography-mass spectrometry grade) was 
used in-house from Milli Q system. Apixaban and apixaban 13C D3 
were purchased from Vivan life sciences.  
Preparation of standard solutions and quality control samples 
Standard solutions of apixaban (100 µg/ml) and apixaban 13C D3 
(100 µg/ml) were prepared in methanol. Intermediate stock 
solutions of both analyte and internal standard (10 µg/ml) were 
prepared in diluent (50% methanol in water) along with standard 
internal dilution (40 ng/ml). Nine level calibrators and four-level 
controls were prepared in human plasma containing sodium citrate 
as anticoagulant ranging from 1-250 ng/ml and 1-125 ng/ml 
respectively.  
Sample preparation 
50 µl of internal standard was added to 200 µl pre-spiked plasma 
samples and 50 µl of diluent has been added to the blank samples in 
prelabelled micro vials. Samples were vortexed to mix well. Samples 
were pretreated with 500 µl of 0.10% orthophosphoric acid, 
vortexed to mix. Apixaban and apixaban 13CD 3 were subjected to 
International Journal of Pharmacy and Pharmaceutical Sciences 
Print ISSN: 2656-0097 | Online ISSN: 0975-1491                            Vol 11, Issue 8, 2019 
Atmakuri et al. 
Int J Pharm Pharm Sci, Vol 11, Issue 8, 39-45 
40 
SPE using celerity deluxe (bed weight 30 mg, volume 1 ml-DVB LP) 
cartridges purchased from Orochem India Pvt Ltd., Cartridges were 
conditioned and equilibrated with 0.90 ml of methanol followed by 
0.90 ml of water. Pretreated plasma samples were dispensed onto 
the cartridges and were washed with 0.90 ml of water. Cartridges 
were allowed to dry under the stream of nitrogen gas and were 
washed with 0.90 ml of 20% methanol in water (twice) before 
drying again. Analyte and internal standard were eluted with 0.75 
ml of acetonitrile and the eluent was collected onto prelabelled 
HPLC vials. 10 µl of the eluent from each sample was injected on the 
LC-MS/MS system.  
Instrumentation and analytical conditions 
Above mentioned extraction procedure was optimized during 
method development and it was validated using ultimate 3000 HPLC 
system interfaced with a TSQ Endura triple quadrupole mass 
spectrometer (Thermo Fisher Scientific Inc). Heated electrospray-
ionization source (HESI) was operated in the positive mode. 
Chromatographic separations were performed using a Hypersil beta 
basic C18 (100×4.6 mm inner diameter, 5 µ particle size; Thermo 
Fisher Scientific Inc) at a column temperature of 40 ℃. 2 mmol 
ammonium acetate in water and acetonitrile were used as mobile 
phase in pump A and pump B respectively without premixing. 
Isocratic program conditions were optimized with the composition 
of phase A ranging from 50 to 20% out of which 20% phase A and 
80% phase B gave optimal results at a flow rate of 0.50 ml/min 
without a splitter. Apixaban and apixaban 13C D3 were selectively 
resolved on the reverse phase column at 2.35 min with a total run 
time of 4.00 min. 
Optimized mass spectrometer parameters used for apixaban 
analysis were mentioned below: sheath gas 50 (arb), auxiliary gas 
pressure 25 (arb), capillary temperature 300 °C, Q2 gas pressure 
1.50 m Torr, ion spray voltage 3500 V, and vaporizer temperature 
300 ℃. Selected reaction monitoring (SRM) transitions for 
quantification were m/z 460.10→443.05 for apixaban and 
464.22→447.06 for apixaban 13C D3 respectively. Representative 
chromatograms and a calibration curve of apixaban obtained during 
method validation are shown in fig. 2 and 3: 
 
 
Fig. 2: Representative chromatograms of apixaban 
 
 
Fig. 3: Calibration curve of apixaban in human plasma from 1-250 ng/ml 
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During validation, the method has been validated for selectivity, 
linearity, precision and accuracy (PA), recovery and stability studies 
as per current United States food and drug administration (USFDA) 
recommendations [14].  
5 Precision and accuracy batches (includes ruggedness and stability 
PA batch) were analyzed with the calibration curve ranging from 1-
250 ng/ml. A straight-line equation (y=mx+c) with 1/x2 weighting 
factor has been used to quantify the back-calculated concentration 
of the calibrators and the coefficient of determination (r2) was 
greater than 0.99 in all 5 batches. Summary of back-calculated 
concentrations and calibration curve parameters from all 5 PA 
batches were mentioned below in table 1-2. 
 
Table 1: Precision and accuracy 
Standard 
name 




0.98 1.95 3.91 7.81 15.63 31.25 62.5 125 250 
P and A-01 0.98 1.91 3.91 7.81 15.66 13.3 64 126.8 249.56 
P and A-02 0.97 2.01 3.5 7.56 14.6 31.2 66.6 130.26 251.69 
P and A-03 1.02 2 3.99 8.01 16.52 33.25 60.53 125.03 255.33 
P and A-04 0.95 1.86 3.55 7.95 15.02 31.03 63.26 126.36 251.03 
P and A-05 1.1 1.99 3.86 8.01 14.96 30.13 60.24 124.57 248.6 
mean±SD 1.00±0.06 1.95±0.07 3.76±0.22 7.87±0.19 15.35±0.76 27.78±8.17 62.92±2.63 126.60±2.24 251.24±2.59 
% CV 5.92 3.43 5.88 2.42 4.94 29.43 4.18 1.77 1.03 
% Nominal 102.78 100 96.26 100.73 98.25 88.9 100.68 101.28 100.5 
Mean statistical data are expressed as mean±SD [n=5] 
 
Table 2: Calibration curve parameters summary 
Result table ID Slope Y-Intercept Regression coefficient [r2] 
P and A-01 0.0043 0.18 1.000 
P and A-02 0.0033 0.16 0.999 
P and A-03 0.0030 0.17 0.999 
P and A-04 0.0043 0.17 1.000 
STABILITY P and A 0.0041 0.17 0.999 
 
Specificity and selectivity of the method were assessed in 6 different 
lots of human plasma containing sodium citrate as an anticoagulant. 
Hemolyzed and lipidemic (each lot) were also used for evaluation of 
selectivity of apixaban. % interference in blank was found to be 
0.89% when compared against the lower limit of quantification 
(LLOQ) area of apixaban. Results were presented below in table 3. 
  
Table 3: Specificity and selectivity 
 Apixaban  Apixaban 13CD3  
Matrix Lot no Area in Blank 




 %Interference at the 
retention time of 
Apixaban 
Area in Blank 




% Interference at the 
retention time of Apixaban 
13 CD3 
LOT 1 872 84476 1.03 100 444921 0.02 
LOT 2 649 86521 0.75 80 468670 0.02 
LOT 3 573 85961 0.67 120 459203 0.03 
LOT 4 921 88753 1.04 104 440031 0.02 
LOT 5 953 92546 1.03 98 441722 0.02 
LOT 6 687 95685 0.72 112 465281 0.02 
LOT 7 
(HEMOLYZED) 
1012 102346 0.99 150 445281 0.03 
LOT 8 
(LIPIDEMIC) 
986 110251 0.89 126 452281 0.03 
 
Intra-day precision and accuracy was evaluated in 6 replicates of 
quality control (QC) samples at LLOQ, low (LQC), middle (MQC) and 
higher (HQC) levels over one PA batch and was found to be between 
0.78-1.03 % and 98.49-101.29 respectively over a range of 0.98-125 
ng/ml. Intra-day precision and accuracy results were presented in 
table 4. 
 
Table 4: Intra-day precision and accuracy 
QC concentration LLOQ QC LQC MQC HQC 
  0.98 3.95 31.25 125 
Mean±SD (n=6) 0.96±0.01 3.89±0.03 31.52±0.25 126.61±1.10 
% CV 1.03 0.85 0.78 0.87 
% Nominal 98.7 98.49 100.87 101.29 
 Mean statistical data are expressed as mean±SD [n=6] 
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Inter-day precision and accuracy experiments were evaluated in 4 
batches at the same levels mentioned above and the results were 
found to be between 2.48-4.29 % and 97.72-102.36 %, respectively. 
Results of Inter-day precision and accuracy were tabulated in table 5.
 
Table 5: Inter-day precision and accuracy 
QC  LLOQ QC LQC MQC HQC 
Nominal concentration 0.98 3.95 31.25 125 
mean±SD (n=24) 0.95±0.03 4.05±0.17 31.50±1.02 126.89±3.15 
% CV 2.67 4.29 3.25 2.48 
% Nominal 97.72 102.36 100.82 101.51 
Mean statistical data are expressed as mean±SD [n=24] 
 
Matrix effect was studied for both apixaban and apixaban 13C D3 in 
eight lots of plasma (6 normal, 1 hemolyzed and 1 lipidemic plasma). 
Internal standard (IS) normalized matrix factor was calculated as a 
ratio of the response ratio of post extracted spiked sample upon 
aqueous sample at both HQC and LQC concentration levels and mean 
IS normalized matrix factor was found to be 1.00. 
Results of IS normalized matrix effect experiment were provided 
below in table 6. 
 
Table 6: Matrix effect experiment 
QC Response ratio of post 
extracted spike sample 




QC Response ratio of post 
extracted spike sample 












0.727 0.729 0.997 
0.191 0.190 1.006 0.717 0.707 1.014 
0.188 0.190 0.990 0.733 0.702 1.044 
0.190 0.190 1.002 0.72 0.693 1.040 
0.189 0.188 1.008 0.694 0.727 0.955 
0.190 0.188 1.014 0.684 0.713 0.960 
0.190 0.187 1.014 0.722 0.724 0.997 
0.190 0.190 0.998 0.709 0.720 0.984 
Mean IS normalized matrix factor of LQC [mean±SD 
(n=8)] 
1.00±0.01 Mean IS normalized matrix factor of HQC [mean±SD 
(n=8)] 
1.00±0.03 
% CV 0.8 % CV 3.3 
Mean statistical data are expressed as mean±SD [n=8] 
 
Mean recovery of apixaban was obtained by calculating the response 
ratio of extracted and aqueous samples at LQC, MQC, HQC levels and was 
found to be 99.22% and 95.25% for apixaban and apixaban 13C D3 
respectively. Results of recovery experiment were presented in table 7. 
 
Table 7: Recovery of apixaban 
QC Response of extracted sample Response of Unextracted sample % Recovery 
LQC (n=6) 3291664 3322320 99.03 
MQC (n=6) 2468748 2491740 99.49 
HQC (n=6) 9874992 9966960 99.13 
Mean recovery (mean±SD) 99.22±0.24 
% CV 0.24 
Mean statistical data are expressed as mean±SD [n=6x3] 
 
Stability experiments in the biological matrix were conducted for 
bench top (10.0 h), freeze-thaw 4th cycle (at-50 °C and at-20 °C), 
auto-sampler (48 h), wet extract (32 h 30 min) and long-term 
storage (at-50 °C) and results were mentioned below in table 8-9 
 
Table 8: Stability experiments in biological matrix 
Comparison QC details Mean±SD (n=6) % CV % Nominal 
Freshly spiked LQC 4.12±0.16 3.91 103.97 
Freshly spiked HQC 125.95±4.83 3.83 100.75 
Stability QC details mean±SD (n=6) % CV % Nominal 
Autosampler stability-LQC (48 h) 4.25±0.25 5.78 107.38 
Autosampler stability-HQC (48 h) 128.54±2.13 1.66 102.82 
FT 4th Cycle LQC (-50 °C) 4.14±0.16 3.86 104.6 
FT 4th Cycle HQC (-50 °C) 133.27±2.90 2.18 106.61 
FT 4th Cycle LQC (-20 °C) 4.22±0.16 3.84 106.43 
FT 4th Cycle HQC (-20 °C) 133.22±3.00 2.25 106.56 
Wet extract stability LQC (32 h 30 min) 3.90±0.10 2.6 98.38 
Wet extract stability HQC (32 h 30 min) 126.94±2.77 2.18 101.54 
Bench top stability (LQC) (10 h) 3.60±0.33 9.08 90.74 
Bench top stability (HQC) (10 h) 139.27±9.77 7.01 111.41 
Mean statistical data are expressed as mean±SD [n=6] 
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Table 9: Long term matrix stability 
Comparision QC details Mean±SD (n=6) % CV % Nominal 
Freshly spiked LQC 3.95±0.12 3.15 99.58 
Freshly spiked HQC 132.31±9.28 7.01 105.84 
Stability QC details mean±SD (n=6) % CV % Nominal 
LTMS LQC-100 d 3.42±0.31 9.08 86.2 
LTMS HQC-100 d 119.65±4.59 3.83 95.71 
Mean statistical data are expressed as mean±SD [n=6] 
 
Sensitivity (Limit of detection or LOD) was performed by 
injecting six replicates of the extracted sample prepared at a 
concentration of 50 pg/ml under the same chromatographic 
conditions and the results were found to be accurate and 
precise. Summarized data of the experiment is presented in table 
10. 
 
Table 10: Limit of detection 
Actual concentration of LOD Mean concentration-pg/ml [mean±SD (n=6)] % CV % Nominal 
50 pg/ml (n=6) 47.88±1.83 3.83 95.77 
Mean statistical data are expressed as mean±SD [n=6] 
 
Reinjection reproducibility was evaluated by re-injecting the entire 
PA batch, which was earlier subjected to analysis. Samples were 
kept in autosampler for 26 h 30 min before subjecting the samples 
for reinjection. Results were provided below in table 11. 
 
Table 11: Reinjection reproducibility 
Sample name Mean±SD (n=6) % CV % Nominal 
LLOQ QC 0.98 pg/ml  0.93±0.06 6.31 94.98 
LQC 3.95 pg/ml  4.12±0.15 3.68 104.22 
MQC 31.25 pg/ml  32.41±1.34 4.14 103.71 
HQC 125.00 pg/ml  125.76±2.00 1.59 100.61 
 Mean statistical data are expressed as mean±SD [n=6] 
 
Dilution integrity was checked in the dilution quality control sample 
diluted up to 2 and 5 times respectively. Samples were processed 
under freshly prepared calibration curve standards. Results of the 
dilution integrity experiment were presented below in table 12. 
 
Table 12: Dilution integrity 
Dilution integrity Dilution factor: 2 concentration Dilution Factor: 5 concentration 
375 375 
Observed concentration (ng/ml) 
mean±SD (n=6) 374.35±3.75 365.46±12.83 
%CV 1 3.51 
%Nominal 99.83 97.46 
Mean statistical data are expressed as mean±SD [n=6], Ruggedness experiment was performed by injecting a freshly prepared PA batch on a 
different column. Results of the experiment were provided below in table 13. 
 
Table 13: Ruggedness 
QC concentration LLOQ QC LQC MQC HQC 
0.95 4.11 31.13 126.43 
mean±SD (n=6) 0.03±3.30 0.04±0.89 1.49±4.77 3.11±2.46 
% CV 97.56 104.09 99.61 101.14 
% Nominal 0.95 4.11 31.13 126.43 
Mean statistical data are expressed as mean±SD [n=6] 
 
DISCUSSION 
The current study has been successfully validated as per USFDA 
guidelines [14]. Validation parameters and acceptance criteria of 
the results are mentioned below in table 14 where the 
requirements for assessment of the data has been clearly 
defined. 
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Table 14: Validation parameters and their acceptance criteria 








Minimum 5-point standards are required for building a calibration curve 
Two consecutive standards should not fail 
First and last calibration standard should not fail 
At least 75 % of the calibration curve standards should be with the acceptable limits for accuracy and precision 
% Accuracy and precision should be within 85-115 % for all standards except LLOQ QC.  
% Accuracy and precision should be within 80-120 % for LLOQ QC 
2 
 




% Accuracy and precision should be within 85-115 % for all QCs except LOQ QC.  
% Accuracy and precision should be within 80-120 % for LOQ QC. 
At least 67 % of the quality control samples should be within specified criteria for precision and accuracy 






% interference at the retention time of the analyte in the blank sample should not be more than 20 % of the peak area 
of analyte 
% interference at the retention time of the internal standard in the blank sample should not be more than 5 % of the 
peak area of the internal standard 
4 Matrix effect Mean matrix factor and is normalized matrix factor should be between 0.85-1.15 
5 Recovery No as such criteria defined for % recovery. The precision obtained for mean and global recovery should be with 









Limit of detection 
(LOD) 
Precision and accuracy of the sensitivity samples should be within 85-115 %  
 
 
On the basis of the results obtained, all experiments were found to 
be within acceptance criteria that were defined above in table 14. 
While assessing the linearity of the calibration curves, % nominal of 
the standard concentrations was found to be between 88.91 to 
102.78. Linearity study results were given in table 1-2. Inter-day and 
intra-day QC data were tabulated in table 4-5 and the data 
represented do not contain any outliers. Method was found to be 
more selective and specific, without any matrix effect and the results 
were presented in table 3 and 6. Mean extraction recoveries were 
found to be 99.22±0.24 and the results were given in table 7. 
During method comparison, it was observed that only few methods 
employed a single step sample extraction [2, 5, 10, 12] by using protein 
precipitation. But protein precipitation is not preferred by many due to 
improper sample cleanup. Techniques like turbulent flow liquid 
chromatography with high-resolution mass spectrometry was used [11], 
but the setup requires highly skilled manpower and it is a costly setup. 
The current method was developed and validated by using a simple and 
single-step solid phase extraction procedure which is relatively cost-
effective, highly specific and sensitive. Further sensitivity of the method 
was successfully evaluated till the lowest detection level i.e., 50 pg/ml, 
whereas the limit of detection in the reported literatures [2-13] is not 
less than 1 ng/ml. Results of LOD were presented in table 10. 
CONCLUSION 
The developed method is highly sensitive, selective and it is a key 
differentiator with a LOD of 50 pg/ml employing just 200 µl of the 
plasma sample. This was achieved due to the proper cleanup of the 
samples using a single-step solid-phase extraction of acidified 
plasma samples. With the ability to analyze over 360 samples per 
day this method is not only suitable for PK study analysis but can be 
validated and used for TDM also provided, the sample quantity must 
be further reduced as the single sample in clinical diagnostics is 
required for performing many other additional tests. This kind of 
method transfer is possible as a recent study [12] conducted on a set 
of blood samples from 116 patients treated with new oral anti-
coagulant reveals that “the results of both specific dilute thrombin 
time (dTT) tests for dabigatran provided the same results as the 
activated partial thromboplastin time (aPTT) screening test in 
comparison with LC-MS/MS as a reference.” The results of both 
specific dTT tests for dabigatran provided the same results as the 
activated partial thromboplastin time aPTT screening test in 
comparison with LC-MS/MS as a reference. Hence, the objective of 
the current research work is fulfilled as it can be applied to conduct 
PK study analysis as well as TDM. 
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